Approval of IL-2 treatment for metastatic melanoma and renal cancer by the US Federal and Drug Administration (FDA) kickstarted a new era of cancer therapy and brought the immunotherapy in the spotlight (4, 5). The gene discussed is IL2; the disease is renal carcinoma.